Hoechst Pakistan Limited has reported a significant improvement in profitability for the half year ended June 30, 2026, while also moving forward with plans to explore a potential acquisition in the pharmaceutical sector.
According to the company’s financial results submitted to the Pakistan Stock Exchange on August 20, 2026, Hoechst Pakistan recorded unconsolidated profit after tax of Rs2.20 billion, compared with Rs1.34 billion in the corresponding period of 2025. This represents an increase of around 63% year-on-year. Earnings per share also rose to Rs227.65, compared with Rs139.34 a year earlier.
The company’s revenue for the six-month period increased to approximately Rs16.67 billion, up from Rs16.28 billion in the same period last year. At the same time, operating profit climbed to about Rs3.76 billion from Rs2.40 billion, highlighting a substantial improvement in operating performance.
On a consolidated basis, the company posted profit after tax of Rs2.19 billion, compared with Rs1.34 billion in the first half of 2025. Consolidated earnings per share increased to Rs227.20 from Rs139.25.
Rs80 Per Share Interim Dividend
Alongside the financial results, the Board of Directors recommended an interim cash dividend of Rs80 per share, equivalent to 800%, for the half year ended June 30, 2026. No bonus or right shares were announced.
Shareholders whose names, along with updated IBAN details, appear on the company’s register on September 2, 2026 will be entitled to the dividend. The share transfer books will remain closed from September 3 to September 4, 2026.
Acquisition Plans Move Forward
A key development alongside the financial results is Hoechst Pakistan’s progress toward a potential strategic expansion.
The company said its Board has authorized management to complete due diligence for the potential acquisition of a pharmaceutical company and work toward finalizing commercial terms, binding offers and definitive agreements. Any transaction remains subject to applicable laws and the necessary corporate and regulatory approvals.
The move follows the Board’s March 24, 2026 decision to evaluate medium- to long-term expansion opportunities, including product partnerships, investment in manufacturing assets and the possible acquisition of a majority stake in a pharmaceutical company.
The Board has also authorized the company’s Chief Executive Officer and designated directors to take the required steps concerning commercial terms, transaction arrangements and financing structures.
Outlook
Hoechst Pakistan’s first-half results show stronger profitability despite only modest growth in revenue. The sharp rise in operating profit and earnings indicates improved overall financial performance during the period.
Meanwhile, the company’s potential acquisition strategy could become an important development for its future growth. However, the transaction is still at the due-diligence and commercial-negotiation stage, meaning the final terms and outcome remain subject to further approvals.
For investors, the combination of higher earnings, a substantial interim dividend and the pursuit of strategic expansion makes the latest announcement an important development for Hoechst Pakistan and the pharmaceutical sector.
